Comprehensive BMJ Network Meta-Analysis Compares Obesity Drugs Head-to-Head
Key Questions
Which obesity drugs show the greatest weight-loss efficacy in the BMJ network meta-analysis?
Tirzepatide and CagriSema led in weight reduction across 262 trials, while only subcutaneous semaglutide demonstrated reductions in mortality and myocardial infarction.
Do any obesity medications improve quality of life beyond the minimal threshold?
The comprehensive BMJ analysis found no drug improved quality-of-life scores beyond the prespecified minimal clinically important difference, despite clear cardiometabolic benefits for some agents.
How should treatment decisions be made given agent-specific differences?
The data support individualized prescribing based on cardiovascular risk profile, tolerability, and potential lean-mass loss rather than relying on a uniform class effect.
A network meta-analysis of 262 trials in BMJ provides definitive comparative effectiveness data: tirzepatide and CagriSema lead in weight loss, but only subcutaneous semaglutide shows mortality and MI reduction. No drug improved QoL beyond minimal threshold. This synthesis challenges simplistic efficacy rankings and reinforces individualized treatment decisions based on CV risk, tolerability, and lean mass loss. A recent deep dive on the GLP-1 class evolution further emphasizes agent-specific differences beyond class effects.